Jodi L. Skiles, MD
Associate Professor of Clinical Pediatrics
Director, Riley Children's Cancer Center Inpatient Service
Medical Director, Pediatric SCT and Immunotherapy
Medical Director, Adolescent and Young Adult Oncology Program
Associate Director, Pediatric Hematology/Oncology Fellowship
- jskiles@iu.edu
- Phone
- 317-274-8806
- Address
-
705 Riley Hospital Drive
ROC 4340
Indianapolis, IN 46202 - PubMed:
-
Bio
I am a homegrown Hoosier. Born and raised in Frankfort, Indiana, I chose to stay close to home for all of my education and training. I recently completed my Pediatric Hematology/Oncology fellowship training at Indiana University and subsequently joined the Department of Pediatrics in July 2012, due in large part to the excellent and collegial atmosphere at Riley Hospital for Children. My position includes 80% protected time for research and 20% clinical time on Pediatric Stem Cell Transplant. Over the last several years, I have spent 50% of my time in Kenya overseeing the Pediatric Oncology program and conducting translational research as part of the robust IU-Kenya Partnership. As my husband and I start a family, the amount of time I spend in Kenya will be decreasing, but we plan to remain firmly invested in the continued success of the program. Socially, I am an avid Colts fan, an outdoor enthusiast, and a competitive game player (especially when it comes to Euchre).
Key Publications
Bell, C., Skiles J., Champion, V., et al. End of life experiences in adolescents dying with cancer. Supportive Care in Cancer: Volume 18, Issue 7 (2010), Page 827-835. DOI: 10.1007/s00520-009-0716-1
Skiles, JL, Imel, E., Christenson J., Bell, J. , Hulbert. Fluorosis because of prolonged voriconazole therapy in a teenager with Acute Myelogenous Leukemia. Journal of Clinical Oncology, Vol 29, no. 32 (2011): 779-782. DOI 10.1200/JCO.2011.35.9604
Marsh, Allen, McClain, Weinstein, Washki, Skiles, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 2012; DOI 10.1002/pbc. Epub ahead of print.
Strother RM, Asirwa FC, Busakhala NB, Skiles JL, et al. AMPATH-Oncology: A model for comprehensive cancer care in sub-Saharan Africa. Journal of Cancer Policy 2013.
Skiles J*, Moormann A*, Koros E, et al. Mentoring future Kenyan Oncology Researchers. Infectious Agents and Cancer 2013, 8:40. http://www.infectagentscancer.com/content/8/1/4
Mostert, S, Njuguna F, Skiles, J, Kaspers, G, et al. Influence of Health-Insurance Status and Hospital Retention Policies on Childhood Cancer Treatment in Kenya. Pediatric Blood & Cancer 2013. ePub ahead of print: DOI: 10.1002/pbc.
Mostert S, Skiles J, Kaspers G. Two overlooked contributors to abandonment of childhood cancer treatment in Kenya: parents’ social network and experiences with hospital retention policy. Accepted to Psycho-Oncology 2013.
Jayachandran D, Ramkrishna U, Skiles J , Renbarger J, Ramkrishna D. Revitalizing Personalized medicine: Respecting Biomolecular Complexities beyond gene expression. CPT Pharmacometrics Syst. Pharmacol. (2014) 3, e110; doi:10.1038/psp.2014.6
Njuguna F, Mostert S, Skiles J, Kaspers G, et al. Abandonment of Childhood Cancer Treatment in Kenya: an Analysis of Causes and Consequences. Arch Dis Child 2014; 0:1-6. doi:10.1136/archdischild-2013-305052.
| Year | Degree | Institution |
|---|---|---|
| 2012 | Fellowship | Indiana University School of Medicine |
| 2009 | Residency | Indiana University School of Medicine |
| 2005 | MD | Indiana University |
| 2001 | BS | Indiana University |
My specific area of interest is the pharmacogenetics of anticancer drugs in children. This involves the investigation of tumor response in children receiving specific chemotherapeutic agents and the sensitivity of these individuals to the toxic side effects of the drugs. My goal is to study the clinical relevance of and the relationships between genotype and phenotype of important drug metabolizing enzymes, drug transporters, and drug receptors expressed in germline DNA. Throughout my research experiences thus far, I have primarily focused on conducting a clinical pharmacology research project at Moi University Teaching and Referral Hospital in Eldoret, Kenya as part of the robust IU-Kenya partnership. This work will hopefully allow us to optimize vincristine use in pediatric patients in Kenya with the potential for future expansion (with collaboration through my mentors at IU) to children around the world.
Clinically, in addition to my service time for Pediatric Stem Cell Transplant, I would really like to utilize my unique combined internal medicine/pediatrics training to develop an Adolescent and Young Adult Oncology Program at IU. There are many young adults diagnosed with cancer each year that are (by default) referred to and treated by adult medical oncologists despite the fact that it has been well-established that this population experiences better survival when treated on pediatric treatment protocols. My goal over the next 1-2 years is to develop both a treatment program and a research platform for AYA cancer patients, specifically regarding high-risk leukemias and pharmacogenetic biomarkers of response to treatment. As part of this program, we have already launched a comprehensive Fertility Preservation Program for pediatric and young adult patients who are receiving fertility-compromising therapy.
Pediatric Hematopoietic Stem Cell Transplant; High Risk Leukemia and genetic predictors of response to therapy; Fertility preservation in pediatric and adolescent oncology patients; Adolescents and Young Adults with cancer; Biomarkers of chemotherapy toxicity.
Desc: Trustee Teaching Award
Scope: University
Date: 2017-05-01
Desc: Alpha Omega Alpha
Scope: School
Date: 2015-07-01
Desc: Indiana Institute of Personalized Medicine Scholar
Scope: School
Date: 2010-07-01
Desc: Oustanding Med/Peds Resident of the Year
Scope: School
Date: 2009-06-01
Desc: Riley Hospital for Children Red Shoes Award
Scope: Department
Date: 2009-05-01
Desc: St. Baldrick's Foundation Scholar
Scope: National
Date: 2009-05-01